FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117083889> ?p ?o ?g. }

• W2117083889 endingPage "2309" @default.
• W2117083889 startingPage "2304" @default.
• W2117083889 abstract "Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).In the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study, 599 hypertensive patients with type 2 diabetes and nephropathy received 6 months of aliskiren (150 mg daily titrated to 300 mg daily after 3 months) or placebo added to 100 mg losartan and optimal antihypertensive therapy. Exclusion criteria included eGFR<30 ml/min per 1.73 m2 and serum potassium>5.1 mmol/l.Baseline characteristics were similar between treatment groups in all CKD stages. The antiproteinuric effects of aliskiren were consistent across CKD stages (19, 22, and 18% reduction). In the stage 3 CKD group, baseline serum creatinine levels were equal, but renal dysfunction, prespecified as a postrandomization serum creatinine elevation>176.8 μmol/l (2.0 mg/dl) occurred more frequently in the placebo group (29.2 vs. 13.6%, P=0.032). Serum potassium elevations>5.5 mmol/l (based on a single measurement) were more frequent with aliskiren (22.5 vs. 13.6%) in stage 3 CKD. Adverse event rates were similar between treatments, irrespective of CKD stage.Aliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline CKD stage in patients with type 2 diabetes, hypertension, and nephropathy." @default.
• W2117083889 created "2016-06-24" @default.
• W2117083889 creator A5003287725 @default.
• W2117083889 creator A5012676820 @default.
• W2117083889 creator A5044496367 @default.
• W2117083889 creator A5048492705 @default.
• W2117083889 creator A5055479743 @default.
• W2117083889 creator A5085592050 @default.
• W2117083889 date "2010-08-06" @default.
• W2117083889 modified "2023-10-16" @default.
• W2117083889 title "Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy" @default.
• W2117083889 cites W1990042304 @default.
• W2117083889 cites W2002384775 @default.
• W2117083889 cites W2004822957 @default.
• W2117083889 cites W2004857031 @default.
• W2117083889 cites W2017268330 @default.
• W2117083889 cites W2031802566 @default.
• W2117083889 cites W2049022568 @default.
• W2117083889 cites W2055864845 @default.
• W2117083889 cites W2069447062 @default.
• W2117083889 cites W2096875294 @default.
• W2117083889 cites W2128451215 @default.
• W2117083889 cites W2137177722 @default.
• W2117083889 cites W2138670606 @default.
• W2117083889 cites W2145632481 @default.
• W2117083889 cites W2146852263 @default.
• W2117083889 cites W2165945094 @default.
• W2117083889 cites W2475261460 @default.
• W2117083889 cites W4300821041 @default.
• W2117083889 doi "https://doi.org/10.2337/dc10-0833" @default.
• W2117083889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2963484" @default.
• W2117083889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20693353" @default.
• W2117083889 hasPublicationYear "2010" @default.
• W2117083889 type Work @default.
• W2117083889 sameAs 2117083889 @default.
• W2117083889 citedByCount "53" @default.
• W2117083889 countsByYear W21170838892012 @default.
• W2117083889 countsByYear W21170838892013 @default.
• W2117083889 countsByYear W21170838892014 @default.
• W2117083889 countsByYear W21170838892015 @default.
• W2117083889 countsByYear W21170838892017 @default.
• W2117083889 countsByYear W21170838892019 @default.
• W2117083889 countsByYear W21170838892020 @default.
• W2117083889 countsByYear W21170838892021 @default.
• W2117083889 crossrefType "journal-article" @default.
• W2117083889 hasAuthorship W2117083889A5003287725 @default.
• W2117083889 hasAuthorship W2117083889A5012676820 @default.
• W2117083889 hasAuthorship W2117083889A5044496367 @default.
• W2117083889 hasAuthorship W2117083889A5048492705 @default.
• W2117083889 hasAuthorship W2117083889A5055479743 @default.
• W2117083889 hasAuthorship W2117083889A5085592050 @default.
• W2117083889 hasBestOaLocation W21170838891 @default.
• W2117083889 hasConcept C126322002 @default.
• W2117083889 hasConcept C126894567 @default.
• W2117083889 hasConcept C134018914 @default.
• W2117083889 hasConcept C159641895 @default.
• W2117083889 hasConcept C198710026 @default.
• W2117083889 hasConcept C2776174234 @default.
• W2117083889 hasConcept C2777180221 @default.
• W2117083889 hasConcept C2778653478 @default.
• W2117083889 hasConcept C2779561371 @default.
• W2117083889 hasConcept C2779838083 @default.
• W2117083889 hasConcept C2779922275 @default.
• W2117083889 hasConcept C2780091579 @default.
• W2117083889 hasConcept C2780288358 @default.
• W2117083889 hasConcept C2780306776 @default.
• W2117083889 hasConcept C2781184683 @default.
• W2117083889 hasConcept C2908929049 @default.
• W2117083889 hasConcept C2909209853 @default.
• W2117083889 hasConcept C555293320 @default.
• W2117083889 hasConcept C71924100 @default.
• W2117083889 hasConcept C84393581 @default.
• W2117083889 hasConceptScore W2117083889C126322002 @default.
• W2117083889 hasConceptScore W2117083889C126894567 @default.
• W2117083889 hasConceptScore W2117083889C134018914 @default.
• W2117083889 hasConceptScore W2117083889C159641895 @default.
• W2117083889 hasConceptScore W2117083889C198710026 @default.
• W2117083889 hasConceptScore W2117083889C2776174234 @default.
• W2117083889 hasConceptScore W2117083889C2777180221 @default.
• W2117083889 hasConceptScore W2117083889C2778653478 @default.
• W2117083889 hasConceptScore W2117083889C2779561371 @default.
• W2117083889 hasConceptScore W2117083889C2779838083 @default.
• W2117083889 hasConceptScore W2117083889C2779922275 @default.
• W2117083889 hasConceptScore W2117083889C2780091579 @default.
• W2117083889 hasConceptScore W2117083889C2780288358 @default.
• W2117083889 hasConceptScore W2117083889C2780306776 @default.
• W2117083889 hasConceptScore W2117083889C2781184683 @default.
• W2117083889 hasConceptScore W2117083889C2908929049 @default.
• W2117083889 hasConceptScore W2117083889C2909209853 @default.
• W2117083889 hasConceptScore W2117083889C555293320 @default.
• W2117083889 hasConceptScore W2117083889C71924100 @default.
• W2117083889 hasConceptScore W2117083889C84393581 @default.
• W2117083889 hasIssue "11" @default.
• W2117083889 hasLocation W21170838891 @default.
• W2117083889 hasLocation W21170838892 @default.
• W2117083889 hasLocation W21170838893 @default.
• W2117083889 hasLocation W21170838894 @default.
• W2117083889 hasOpenAccess W2117083889 @default.

• next